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Summary: Cell viability and number of granulocyte-monocyte colony forming units (CFU-GM) were systemati-
cally assessed in 57 patients who had undergone transplantation of the autologous bone marrow for treatment of
haematologic malignancies. Bone marrow cell cultivation in agarose with feeder layers appeared inferior to that
performed in agarose with recombinant human granulocyte-monocyte colony stimulating factor and methylcellulose
with phytohaemaglutinin leukocyte-conditioned medium. Since the transplant cells were frozen in liquid nitrogen
between harvesting and reinfusion, the following samples were tested: buffy coat cells, buffy coat cells immediately
after addition of dimethylsulphoxide, cell sample that had been frozen for 24 hours, and frozen transplant cells at
the time of thawing and transplantation. Each procedural step decreased both cell viability and the number of CFU-
GM, but since the lymphohaematologic recovery in all patients followed the pattern reported in the literature for
high-quality transplants, we concluded that our transplants retained the necessary number of progenitor cells. It
appears that the best strategy for dynamic assessment of the transplant quality would be to perform tests after every
step of the transplant processing. Cell viability and number of progenitors per body weight in transplants were also
found to be associated with probability of neutrophil reconstitution after bone marrow reinfusion.
Introduction the numbers of lymphocytes and platelets (1, 7) in the
Autologous bone marrow transplantation is a modern Post-transplantation time period,
and powerful method for treatment of haematological Since there is still no worldwide standardized in vitro
and non-haematological malignancies (1). However, the technique for CFU-GM cultivation, the choice of
methods for bone marrow harvesting, freezing and stor- method depends on laboratory practice, i.e. available
ing (2, 3), as well as laboratory methods for assessing technologies, reproducibility and training. It has been
the number of granulocyte-monocyte/macrophage col, suggested that each routine clinical laboratory should
ony forming units (CFU-GM) in the transplants (4) vary have its own standard (8)t
substantially in different transplantation centres. Al-
though the pluripotent stem cell is responsible for lym- The aim of this investigation was an evaluation of the
phohaematopoietic recovery of a patient, the committed CFU-GM content and cell viability characteristics of
progenitor cell grown in vitro (CPU) is strongly related bone marrow transplants during their preparation for
to the posttransplantation recovery of blood cell popula- transplantation. Since 1988, our team has performed a
tions (2) and is thus used for estimation of the transplant number of autologous bone marrow transplantations (9),
quality. Its content in the transplant mostly affects the and the resulting data has enabled us to define the most
numbers of leukocytes and neutrophils (5, 6), but also rational scheme for the procedure and our respective lab-
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oratory standards. The results of our investigation were
improved by relating the laboratory test results of the
bone marrow transplants to the posttransplantation
haematological recovery of neutrophils in peripheral
blood of the patients.
Patients and Methods
Patients
The study was performed on 57 bone marrow samples from pa-
tients undergoing autologous transplantation in the period from
March 1988 to July 1993. All had haematological malignancy: 30
acute myeloid leukaemia, 19 acute lymphoid leukaemia, five
Hodgkin's disease and three non-Hodgkin lymphoma. There were
33 males and 24 females, median age of 24 years (range 2 to 54).
Patients were consolidated with high or intermediate doses of cyto-
sine-arabinoside. Three protocols were used for complete mye-
loablative therapy before transplantation:
(a) total body irradiation (12 Gy, fractionate) after cyclophospha-
mide 2 X 60 mg/kg body weight (N = 32, 56.1% of the patients),
(b) cyclophosphamide 2 X 60 mg/kg and busulphan 4 X 4 mg/kg
body weight (N = 18, 31.6%), and
(c) (BEAM) scheme (N = 7,12.3%). BCNU 1 X 300 mg/m2, etho-
poside (VP16-213) 4 X 200 mg/m2, ara-C 8 X 200 mg/m2 and
melphalan 1 X 140 mg/m2. The first two protocols were used for
all malignancies, and the third one for lymphomas only.
Methods
Buffy coat was prepared from bone marrow on a COBE 2991 Blood
Cell Processor, chilled on ice to 4 °C, mixed with dimethylsulph-
oxide (volume fraction 0.1) as cryoprotective agent at the same tem-
perature, frozen using a controlled freezing system and stored in li-
quid nitrogen at — 196°C. Cell viability and clonogeneic activity
were tested in three preparation steps before transplant reinfusion
(buffy coat, buffy coat immediately after addition of dimethylsulph-
oxide, and buffy coat plus dimethylsulphoxide 24 hours after freez-
ing), and in a transplant sample at the time of reinfusion.
Mononuclear cells were prepared from the bufify coat by gradient
separation (1.077 kg/1) and washed twice in RPMI-1640 medium
(Immunology Institute, Zagreb, Croatia). Samples with dimethyl-
sulphoxide were slowly diluted immediately after thawing 1:10
with medium containing 0.01 volume fraction of L-glutamine (L-
glutamine 200 mmol/1, Gibco, Paisley, UK) and 0.1 volume frac-
tion of fetal calf serum (Gibco). Cell viability was tested by the
trypan blue exclusion method (Trypan blue 0.4%, Sigma, USA).
Clonogeneic activity was assessed using three methods. For 33
samples, 105 mononuclear cells were mixed with medium contain-
ing fetal calf serum and agar (final volume fractions 0.1 and 0.03,
respectively) in a volume of 1 ml, then layered over a 5 to 10
day-old feeder layer prepared from healthy donor leukocytes (10).
Cultivation on feeder layers was always done in parallel with a
control sample containing a known number of progenitors; if the
number of CFU-GM in the control was 10% less or greater than
expected, the feeder layer was replaced with a new one. For 9
samples, 105 mononuclear cells were resuspended in medium con-
taining the same quantities of fetal calf serum and agar, arid 250 ng
of recombinant human granulocyte-monocyte colony stimulating
factor (GM-CSF) in 1 ml final volume (GMC 89-107, Sandoz
Pharma AG, Basel, Switzerland). For the remaining 15 samples,
5 Χ 104 mononuclear cells were mixed with 0.5 ml of commer-
cially prepared medium (MethoCult H4432, StemCell Technol-
ogies Inc, Vancouver, Canada) containing methylcellulose, phyto-
haemagglutinin leukocyte-conditioned medium (volume fraction
0.1) and 3 X 103 U/l of recombinant human erythropoietin (11).
For all methods, plating was done in triplicate and the average
number of CFU-GM was calculated.
Data analysis
All the data are numerical. They are presented with the median
value, and the 10th to 90th percentile range, because all values
except cell viability were not normally distributed. The differences
between groups were tested using the Wilcoxon test for matched
pairs and Kruskal-Wallis non-parametric analysis for several
group means.
The probable time of haematopoietic engraftment was taken as the
posttransplantation day on which the neutrophil counts in the pe-
ripheral blood reached values of 0.2 X 105/1 and 0.5 X 105/1
respectively, as calculated and constructed by the Kaplan-Meier
method of incomplete observation. Patients were censored if they
did not attain the count by the last day of the follow up. The influ-
ence of various laboratory conditions on the engraftment kinetics
was assessed by using Cox's forward stepwise multivariate regres-
sion analysis. TTie following variables were analysed: transplant
volume, total number of mononuclear cells, number of mononu-
clear cells per transplant volume and per body weight, cell viability,
total number of CFU-GM, and number of CFU-GM per 105 mono-
nuclear cells and per body weight. All reported p-values referred
to two-sided tests, and were considered significant if less then 0.05.
Results
For each transplant, samples in four different steps of
preparation were analysed: buffy coat cells after ficoll
separation, buffy coat cells immediately after addition
of dimethylsulphoxide, the cells that had been frozen at
least 24 hours, and the cells from the frozen transplant
at the day of transplantation. Average cell viability and
number of CFU-GM in the samples are presented in ta-
ble 1. After each procedural step, the viability of cells
was significantly lower, except between the first two
samples (buffy coat and buffy coat with dimethylsulph-
oxide). Similarly, the number of the CFU-GM was sig-
nificantly lower after each procedural step except for the
difference between samples with dimethylsulphoxide
before and 24 h after freezing (tab. 1, ρ < 0.05).
Table 2 presents the number of CFU-GM according to
laboratory method used for stimulation of the growth of
bone marrow cells in the culture: feeder layers, agarose
with recombinant human GM-CSF, methylcellulose with
phytohaemagglutinin leukocyte-conditioned medium.
There was no significant difference in CFU-GM content
in relation to the cultivation method, although, com-
pared with the other two techniques, values obtained
with cells from the fresh buffy coat were considerably
lower if feeder layer was used (tab. 2,40 compared with
50 and 51 CFU-GM per 105 mononuclear cells). In
general, however, the data showed the same pattern of
decreasing CFU-GM values as described in table 1, i.e.
lower numbers of the CFU-GM after each step of the
processing of the transplant.
We also investigated CFU-GM content according to the
type of malignancy and therapy,*as reported in the Pa-
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Tab. 1 Cell viability and number of granulocyte-monocyte col- with haeraatological malignancy, prepared for autologous bone
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- Buffy coat frozen >24 hours






























- Buffy coat 4- dimethylsulphoxide
- Bufify coat frozen >24 hours

























p-values represent probabilities derived from testing the differences transplant samples defined in the first column of the table. NS
of viability and CFU-GM numbers between procedural steps dur- not significantly different (p > 0.05).
ing the preparation of buffy coat; letters B, C and D designate
Tab. 2 Number of granulocyte-monocyte colony forming units cal malignancy, prepared for autologous bone marrow transplanta-
(CFU-GM) in bone marrow samples of patients with haematologi- tion according to the cultivation methods
















































p-values represent probabilities derived from testing the differences ods using non-parametric analysis of variance,
of CFU-GM numbers between all three different cultivation meth-
tients section, but there was no significant difference be^
tween respective patient groups (data not shown).
In patients presented in this study (fig. 1), a neutrophil
count in the peripheral blood of 0.2 X 105/1 was attained
between 7 and 58 days after transplantation (median 14
days, two patients died before achieving the count), and
of 0.5 X 105/1 between 11 and 72 days after transplanta-
tion (median 22 days, three patients died before achiev-
ing the count). Table 3 presents laboratory values ana-
lysed for their influence on the engraftment kinetics of
neutrophil cells in peripheral blood of the patients. Only
cell viability and number of granulocyte-monocyte pro-
genitors per kg of body weight were found to be inde-
pendently and significantly associated with the prob-
ability of haematopoietic reconstitution, both determined
on the basis of neutrophil concentrations, and with nega-
tive correlation coefficients.
Discussion
Cell viability and number of CFU-GM, together with the
total number of mononuclear cells in a bone marrow
transplant, are basic indicators of the quality of a
transplant, especially if freezing of autologous bone
Eur J Clin Chem Cliri Biochem 1995; 33 (No 10)
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Tab. 3 Laboratory characteristics of the transplant samples in relation to engraftment kinetics of the






































Influence on the attainment of the number of neutrophils





















































The influence of transplant characteristics on the attainment of neu-
trophil counts was tested using the Cox multivariate test; the results
of analyses are presented with χ2-values, corresponding p-values
and correlation coefficients (r) for variables that are significantly
associated with engraftment kinetic. NS — not significant
(p > 0.05).
marrow is utilized. The quality of the sample must al-
ways be verified before transplantation, because cryo-
protective agents, such as dimethylsulphoxide, and cool-
ing and storing techniques can irreparably damage the
cells (12). Procedure-related and method-related
decreases in cell viability and progenitor content are ex-
pected, but the minimal transplant quality, which will
allow a good and fast posttransplantation haematologic
recovery, must be both monitored and achieved (fig. 1).
Inasmuch as all our patients recovered haematologically
within the time period reported as clinically favorable
(1, 5, 13, 14), our transplant procedure can be consid-
ered as serviceable. Multivariate analysis reported in ta-
ble 3 revealed that the only significant laboratory factors
influencing the delay of neutrophil recovery (presented
in fig. 1) are cell viability and progenitor content related
to the body weight. This is in accord with some studies
(2, 5, 6), while others have failed to confirm it (15).
Only the recovery of neutrophils was studied because
these cells mature and differentiate directly from CFU-
GM progenitors. Low correlation coefficients (table 3)
suggest that some other conditions, different from those
investigated, were also associated with neutrophil en-
graftment, and that viability and CFU-GM number can-
not be used directly for predicting the day of attaining
the desired concentration. However, prediction of post-
transplantation recovery was not the aim of the study.
We simply wanted to assess the need for a valuable labo-
ratory technique for testing the validity of the transplant
preparation procedure.
Viability and CFU-GM values shown in tables 1 and
2 are actually used as our laboratory standards of the
autologous bone marrow transplant quality. It should
also be noted that they do not represent minimal,
optimal or maximal values, but rather the values clini-
cally related to good haematologic recovery. Our sub-
20 30 40 50 '
Time after transplant reinfusion [d]
60 70
Fig. 1 Cumulative probability of attaining neutrophil counts of
0.2 X 109/1 and 0.5 X 109/1 after autologous bone marrow trans-
plantation in 57 patients with haematological malignancy (censored
data are indicated with an open circle)."?
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sequent follow up of 20 new patients (data not shown)
revealed the same transplant quality and the same
pattern of patient recovery after transplantation, except
in one patient whose recovery was very slow and
the number of CFU-GM low (11 CFU-GM per 105
mononuclear cells in buffy coat).
Although the data did not prove statistically significant,
cell cultivation using recombinant human GM-CSF and
phytohaemagglutinin leukocyte-conditioned medium in
methylcellulose as stimulating factors yielded results
that appeared much better than those obtained with
feeder layers (tab. 2). The differences were so impres-
sive (tab. 2) that we believe that feeder layers should be
avoided if possible, at least for routine laboratory test-
ing. The facility of operation and accuracy of results
using completely prepared and standardized media, such
as that with phytohaemagglutinin leukocyte-conditioned
medium in methylcellulose, support their use over any
other technique in the routine laboratory procedures. In
addition, the general adoption of such media would per-
mit direct comparison of data from different laborato-
ries, which in turn would allow the introduction of
multicentre evaluations.
Some centres for monitoring transplant quality use
methods for CFU-GM cultivation before freezing, some
after freezing and some before and after as a standard
(2). We feel that the best strategy of a dynamic assess-
ment of the transplant quality would be to perform stan-
dardized tests after every step, using any chemical or
physical procedure, i. e. in fresh samples before and after
adding cryoprotective agent, in the sample stored in li-
quid nitrogen, and finally in a transplant sample at the
time of reinfusion. With this type of laboratory routine,
any patient can be individually evaluated (values after
the procedure related to values before the procedure), as
well being compared with any other patient analysed for
cell progenitor content and cell viability in the same or
any other clinical laboratory.
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